Incidence of atypical nontraumatic diaphyseal fractures of the femur. - Wikidata - awgldk - TriplyDB

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

http://www.wikidata.org/entity/Q44364497

about

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research Bisphosphonate drug holiday: choosing appropriate candidates Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study.The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate Histology of 8 atypical femoral fractures: remodeling but no healing Lateral Femoral Bowing and the Location of Atypical Femoral Fractures.Atypical femoral fracture combined with osteonecrosis of jaw during osteoporosis treatment with bisphosphonate.Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.Current perspectives on bisphosphonate treatment in Paget's disease of bone.Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs Questioning the association between bisphosphonates and atypical femoral fractures Risk of atypical femoral fracture during and after bisphosphonate use.Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications Hypophosphatasia and the risk of atypical femur fractures: a case-control study.Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study.Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents.Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions Bisphosphonate-induced atypical subtrochanteric femoral fracture.Treatment of Pathological Bone Fractures in a Patient with McCune-Albright Syndrome.The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference?Are race and sex associated with the occurrence of atypical femoral fractures?CORR Insights®: Are race and sex assessment associated with the occurrence of atypical femoral fractures?"Atypical" atypical femur fractures and use of bisphosphonates.A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate.Bisphosphonates and atypical subtrochanteric fractures of the femur.

P2860

Q26782621-6F46146F-077E-4CE8-A0D5-7B03E3CDF54C Q26782834-167F1428-5ED3-469E-BFB1-F7C9A2D0574F Q27004682-8339FB82-D10A-450E-B540-766EE171DDF2 Q27026618-F8F2989D-6D69-474F-856E-F8D565A39138 Q27027254-2693F1F2-AF41-4407-B828-F06C15D8C726 Q28079133-0E913E0B-F1B9-4370-96DC-F8DE4DBF0750 Q30236007-E5976726-5594-4011-BAAD-5756BD7845DB Q31026858-EB0C6012-8A4A-4002-8B3A-16A388D72AAB Q33681406-306D263F-AC6C-47D4-90CB-829D65B9D3B4 Q33700394-CFC80A8D-DC6C-46C9-A110-777CC92E4AA4 Q33774987-EEC758B1-81C0-492C-8A88-C02458E114A4 Q33781081-F7D590D6-2FB5-4B00-BEE7-CD211B0DC44A Q33822053-EDA26DDF-C284-4CBC-B5FE-952E39A90744 Q34272136-5E285A6F-4F63-47B0-9F1F-B2073F5BA517 Q34272165-84B104E1-2F80-4878-A2D5-DA0821D0C9BF Q34566340-AB67EAF0-CE3C-478E-865C-F8336AF64FB7 Q34626680-FDFA917F-3DA4-43D4-9563-2B90C86CE658 Q34758541-B6C5D183-7AA3-405B-B59D-C71132C0FD6F Q34899110-7DE9D5DB-119F-4752-ABCD-F7E55F9F10C9 Q35197628-3AD5557E-64C0-4499-AF8A-70F23A133611 Q35780856-5CD5ABCE-76DE-475C-8BD0-5D7A822DC5DA Q36099672-8FAA6280-3033-430E-B504-F9ADBE4C4AB9 Q36100929-797A5F00-9BCE-4310-8485-A722C13012F1 Q36258041-3E882716-22AC-4BE3-B26A-681BC2FD80A1 Q36523054-A02B28B6-899B-461A-80C6-D64D89288C27 Q36584072-81105864-DFF4-4D8A-A767-5724C03086EA Q36589370-BF7C38B6-3A81-457B-8F7D-DAD96A0A2206 Q36989638-CBA274D6-FE56-4B7B-BB71-2E6FD4E6877F Q37018032-091DFC8D-C3CB-4E6B-AF7F-23A9C03B0F2F Q37046213-1C815713-CD1E-4DAC-8F8B-D504EEE47552 Q37058784-A0123B93-21C9-489D-8236-E83D70E3DF21 Q37357615-420CF418-C2EF-4362-AF73-9518FF0BEB56 Q37392984-846202CC-EBFB-4B58-92EA-056AAE9A851C Q37413331-E038A4AE-BBE2-48AD-A662-B57E8F187057 Q37470866-7D7FC91E-F730-4A4D-86C6-C38E02186652 Q37563703-28FEF78D-0B2C-44A8-B514-EC29D08F3096 Q37563794-3FA3DBFC-DA01-40DE-B106-FA963E44E97A Q37653262-28B059F8-2288-42CE-A462-A5621BB851C3 Q37720665-678471E5-DA08-406D-8A4F-C87F8AE03AE4 Q37733851-4A9866FD-488E-4507-A2D0-A28CEDC99B5D

P2860

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

http://www.wikidata.org/entity/Q44364497

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@en

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@nl

type

label

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@en

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@nl

prefLabel

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@en

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@nl

P1433

Q44364497-FCF42DDE-E162-4C66-9134-6D9BD890810D

P1476

Q44364497-9CC44632-5342-4429-9A5C-91AC69DAE488

P2093

Q44364497-86DBFE03-52E6-4AAD-AE26-4AC2DCB65307

Q44364497-8A003F71-6BD0-4061-9E94-14794CC4EABE

Q44364497-93E15D4A-B94A-45CB-9DD3-978463D7FA50

Q44364497-DD65EE5A-82FC-44D5-A179-C54603687C71

Q44364497-DDED125C-5B62-49A7-9AAF-6A5A12F7077B

Q44364497-E26F0D84-A4DF-4FC7-8DE8-7EE03A16AC23

Q44364497-E563D81D-1011-48A2-8162-B2E6A2799B51

Q44364497-FC9A5B3D-A981-49A6-AF57-CBFC24988700

Q44364497-FF18877D-93A4-4789-9599-1674031102B3

P2860

Q44364497-020FDC40-1FAE-4C56-BC82-C4DEA167A1AF

Q44364497-24BE4844-001A-4617-9BF0-451A71D03CE6

Q44364497-252B0CF5-D7B5-4DB0-9AB9-31402A5CB6B6

Q44364497-26626227-652F-49D0-9ECD-C644922AEB3D

Q44364497-27AA5F20-D3AA-4ADB-8AA9-BD144BDDCB5D

Q44364497-38863054-9116-44B9-9F1E-B1AAB3320E30

Q44364497-3E9D0A10-6DEE-4C28-A0BC-B80FAF21D72E

Q44364497-447C7307-E399-4E41-B788-4723B08D70EE

Q44364497-527C4DBD-3BED-40C0-AFA6-751C7C075C30

Q44364497-52EBCEB5-BE1B-4B55-BD34-86FB7F16F657

P304

Q44364497-905DFE1E-63FD-4C91-9BF9-A36FE1402623

P31

Q44364497-A143BE5E-DB71-426B-AABA-324F7912EBEA

P356

Q44364497-7F29D83D-C97F-42BF-8C39-8FBF5B6D80D2

P433

Q44364497-5DF5BAA6-C574-4B67-8F69-489225814F18

P478

Q44364497-DDB9A011-37E7-474B-9AF7-E8CD304426E3

P577

Q44364497-B6DBA3C1-71B0-4610-91CB-10B909B80195

P5875

Q44364497-8F72578B-A938-412D-A942-2099D7D316A4

P698

Q44364497-7F4D59EB-9414-4DF0-AC6D-A86870232F86

P356

P1433

Journal of Bone and Mineral Research

P1476

Incidence of atypical nontraumatic diaphyseal fractures of the femur.

@en

P2093

Annette L Adams

http://www.w3.org/2001/XMLSchema#string

Denise F Greene

http://www.w3.org/2001/XMLSchema#string

Eric O Eisemon

http://www.w3.org/2001/XMLSchema#string

Hui Zhou

http://www.w3.org/2001/XMLSchema#string

Raoul J Burchette

http://www.w3.org/2001/XMLSchema#string

Richard M Dell

http://www.w3.org/2001/XMLSchema#string

Stuart L Silverman

http://www.w3.org/2001/XMLSchema#string

Susan M Ott

http://www.w3.org/2001/XMLSchema#string

Tadashi T Funahashi

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials.

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

P304

2544-2550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.1719

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230573462

http://www.w3.org/2001/XMLSchema#string

P698

22836783

http://www.w3.org/2001/XMLSchema#string